Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment. Its proprietary RPx platform is based on an engineered HSV-1 backbone designed to maximize immunogenic cell death and systemic anti-tumor immune response. Lead product RP1 (vusolimogene oderparepvec) is being evaluated in melanoma and non-melanoma skin cancers, with a BLA submitted to the FDA in combination with nivolumab for anti-PD-1 failed advanced melanoma, granted priority review with a PDUFA date of July 22, 2025.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-05-22 | 2025-03-31 | 0001737953-25-000009 | EDGAR | 79K words |
| 2024-05-16 | 2024-03-31 | 0001737953-24-000008 | EDGAR | — |
| 2023-05-18 | 2023-03-31 | 0001737953-23-000009 | EDGAR | — |
| 2022-05-19 | 2022-03-31 | 0001737953-22-000010 | EDGAR | — |
| 2021-05-20 | 2021-03-31 | 0001104659-21-069611 | EDGAR | — |
| 2020-06-03 | 2020-03-31 | 0001047469-20-003318 | EDGAR | — |
| 2019-06-28 | 2019-03-31 | 0001047469-19-003946 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-03 | 2025-12-31 | 0001628280-26-004805 | EDGAR | 55K words |
| 2025-11-06 | 2025-09-30 | 0001628280-25-049884 | EDGAR | — |
| 2025-08-07 | 2025-06-30 | 0001737953-25-000013 | EDGAR | — |
| 2025-02-12 | 2024-12-31 | 0001737953-25-000004 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001737953-24-000015 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001737953-24-000013 | EDGAR | — |
| 2024-02-08 | 2023-12-31 | 0001737953-24-000004 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001737953-23-000017 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001737953-23-000013 | EDGAR | — |
| 2023-02-09 | 2022-12-31 | 0001737953-23-000005 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001737953-22-000023 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001737953-22-000014 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-03 | 0001104659-26-009510 | EDGAR | 2K words |
| 2026-01-12 | 0001104659-26-002721 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107438 | EDGAR | — |
| 2025-10-20 | 0001104659-25-100605 | EDGAR | — |
| 2025-09-18 | 0001104659-25-091066 | EDGAR | — |
| 2025-09-04 | 0001104659-25-087464 | EDGAR | — |
| 2025-08-07 | 0001104659-25-074989 | EDGAR | — |
| 2025-07-22 | 0001104659-25-069489 | EDGAR | — |
| 2025-06-24 | 0001104659-25-062122 | EDGAR | — |
| 2025-05-22 | 0001104659-25-051847 | EDGAR | — |
163 total filings indexed. 134 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001737953 |
| Ticker | REPL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.replimune.com |
| Listed | 2018-07-20 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report